Ascendis Pharma Announces Strategic Partnership with Teijin …
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan. – Ascendis Pharma is eligible to receive $70 million...
Healthcare | News - TEIJIN
2024年10月31日 · Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment[Teijin Pharma] (PDF: 303.2 KB)
Teijin Pharma Ltd. (Teijin Pharma Ltd.) - 药物管线_专利_临床试 …
Teijin Pharma now has the rights to commercialize Skytrofa in the country along with TransCon PTH and TransCon CNP. Ascendis Pharma has pocketed $70 million in exchange for the Japanese rights to the FDA-approved long-acting growth hormone Skytrofa and …
2023年3月6日 · Under the terms of the license agreement, Teijin Pharma will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize the candidate for all potential indications. Teijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial
2024年6月6日 · To complement CureApp’s ongoing marketing and sales activities, Teijin Pharma will provide information about CureApp HT to medical institutions throughout Japan, aiming to expand the number of prescribing facilities and prescriptions. I am delighted to collaborate with CureApp, a leading DTx company, in promoting the adoption of CureApp HT.
Teijin Pharma Limited Applies for Manufacturing and Marketing …
2024年12月16日 · Tokyo - Teijin Pharma Limited announced today that it has applied for manufacturing and marketing approval in Japan for palopegteriparatide (developed as TransCon PTH), a new prodrug developed by Ascendis Pharma A/S (Nasdaq: ASND) for the treatment of adults with hypoparathyroidism.
Ascendis Pharma Announces Strategic Partnership With Teijin …
2023年11月29日 · Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.
Merz and Teijin announce partnership to bring XEOMIN ...
2017年10月12日 · Upon the marketing approval of XEOMIN®(incobotulinumtoxinA), Merz will be responsible for the product manufacturing and supply and Teijin Pharma will manage commercial activities in Japan.
Teijin Pharma Grants Global Exclusive License for Investigational …
2023年3月6日 · Tokyo - Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, announced today that it has entered into an exclusive global license agreement with Novartis to research, develop, manufacture and commercialize an investigational preclinical candidate for proteinuric kidney diseases.
Merz and Teijin Announce Partnership to Bring Xeomin ... - Merz Pharma
2017年10月12日 · Teijin Pharma Limited, the core company of Teijin Group’s healthcare business will prepare and file the marketing approval application. Upon the marketing approval of Xeomin ® (incobotulinumtoxinA), Merz will be responsible for the product manufacturing and supply and Teijin Pharma will manage commercial activities in Japan.